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At the time of Dr Fitzpatrick’s entrance into the field of
dermatology, melanoma was a rare tumor. From his interest
in the basic biology of the pigment cell he turned to the
malignant melanocyte for study. Initially the cell line of origin
of melanoma was unclear. Melanoma was recognized
usually in an advanced form, treated by surgeons and
evaluated histopathologically by pathologists. It was most
often fatal to the patient. The subtypes of melanoma were
undefined. Surgery of the tumor was often radical, with as
much as hemipelvectomies being performed for primary
melanomas on the lower extremities. Prognostic factors
were unclear and sunlight was not fully implicated in the
etiology.
The earliest contribution of Dr Fitzpatrick was the
description of the clinical features of melanoma in the book
Tumors of the Skin (Fitzpatrick and Clark, 1963). His interest
in melanoma led to the recruitment of Dr Wallace H. Clark,
Jr to the Massachusetts General Hospital. Dr Clark had a
basic interest in melanocyte biology and melanoma. From
this collaboration, the first pigmented lesion clinic (PLC) in
the United States was established with Drs Fitzpatrick,
Wallace H. Clark, Jr, John Raker, and Martin C. Mihm, Jr.
The clinic began meeting regularly on the first of April, 1966
and patients were readily recruited to this clinic. From
studies of primary tumors over these years, the classifica-
tion of melanoma was developed and published in 1969
(Clark et al, 1969). The appreciation of the unique diagnostic
features of melanoma was a result of the combined obser-
vations of the members of the PLC and led to the publi-
cation of an atlas of clinical diagnosis of early melanoma,
the first such publication in color in the New England
Journal of Medicine (Mihm et al, 1973). That publication was
reprinted by the American Cancer Society and widely
distributed in the United States to practicing physicians.
An outgrowth of the PLC was the formation in 1972 of the
Melanoma Clinical Cooperative Group (MCCG), supported
by funds derived from President Nixon’s ‘‘war on cancer’’.
This group, conceptually formulated by Dr Fitzpatrick,
included Dr Alfred W. Kopf and others at New York
University, Dr Wallace H. Clark, Jr, who had by then moved
to Temple University, and Dr M. Scott Blois, at the University
of California at San Francisco. The goal of the MCCG was
to study the natural history of cutaneous melanoma and
elucidate its clinical and prognostic factors. It was the first
NIH funded cooperative group studying a single cancer,
which was, in addition, not conducting therapeutic trials.
Dr Arthur J. Sober joined the group in 1973 and went on
to become the coordinator of the study. The publications
that were forthcoming from the MCCG included one of
the first series of prognostic studies of melanoma employ-
ing multivariant analysis, which resulted in a clearer under-
standing of the prognosis in patients with this disease (Day
et al, 1982a; Day et al, 1982b; Day et al, 1982c). Drs Ronald
Malt and Calvin Day, utilizing the patient experience from
the MCCG, published one of the first editorials recommend-
ing narrower margins for melanoma in the New England
Journal of Medicine in 1982 (Day et al, 1982d). The PLC
indeed became a model for multidisciplinary approaches to
this disease, and has now been replicated throughout the
world.
One of the special interests of Dr Fitzpatrick was the role
of sunlight in the etiology of malignant melanoma. He
described the Fitzpatrick skin phototypes, which have
proved to this day very helpful in classifying individuals
and their sensitivity to the sun. Through his efforts and those
of Dr Madhu A. Pathak and others, the first sunscreens were
tested and developed for use among the public in the
1980s. From the data accumulated in the PLC files, Dr
Robert Lew published in 1983 a paper documenting the
association of blistering sunburns and increased risk of
melanoma development (Lew et al, 1983). These observa-
tions, along with the rarity of melanoma in non-sun-exposed
areas of the skin, were useful in helping to ban supersonic
transport flights in the United States (Environmental Impact
of Stratospheric Flight, 1975). Dr Fitzpatrick not only
published on this issue, but also appeared before a
congressional panel supporting the restriction of SST flight
to protect the ozone layer (Statement of Thomas B.
Fitzpatrick, 1975). Similar data were used to support the
removal of ozone depleting CFCs from aerosol sprays and
automobile radiators in reports by the National Academy of
Science (Fitzpatrick and Sober, 1979).
It is clear that although Dr Fitzpatrick entered the scene
of melanoma biology at the time when the tumor was of
unclear etiology, highly lethal and also treated by radical
approaches, by the end of his career his contributions
furthered the early recognition of melanoma and its pre-
cursors, helped establish sunlight as a factor in etiology and
also elucidated predictive factors to determine patient
outcome. He was also instrumental in training a generation
of melanoma investigators who continue his work, includ-
ing Dr Martin C. Mihm, Jr, Dr Calvin Day, Jr, Dr Arthur
Rhodes, Dr Howard Koh, Dr Kowichi Jimbow, Dr Martin
Weinstock, Dr Richard Langley, Dr Arthur J. Sober, and Dr
Hensin Tsao, among others.
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